hydroxychloroquine has been researched along with Bed Sores in 1 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alser, O | 1 |
| Mokhtari, A | 1 |
| Naar, L | 1 |
| Langeveld, K | 1 |
| Breen, KA | 1 |
| El Moheb, M | 1 |
| Kapoen, C | 1 |
| Gaitanidis, A | 1 |
| Christensen, MA | 1 |
| Maurer, LR | 1 |
| Mashbari, H | 1 |
| Bankhead-Kendall, B | 1 |
| Parks, J | 1 |
| Fawley, J | 1 |
| Saillant, N | 1 |
| Mendoza, A | 1 |
| Paranjape, C | 1 |
| Fagenholz, P | 1 |
| King, D | 1 |
| Lee, J | 1 |
| Farhat, MR | 1 |
| Velmahos, GC | 1 |
| Kaafarani, HMA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Non-ventilated Prone Positioning in the COVID-19 Population[NCT05957588] | 216 participants (Actual) | Interventional | 2021-10-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for hydroxychloroquine and Bed Sores
| Article | Year |
|---|---|
Multisystem outcomes and predictors of mortality in critically ill patients with COVID-19: Demographics and disease acuity matter more than comorbidities or treatment modalities.
Topics: Acute Kidney Injury; Adult; Age Factors; Aged; Aged, 80 and over; Antimalarials; Boston; Comorbidity | 2021 |